Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9921258 | European Journal of Pharmacology | 2005 | 4 Pages |
Abstract
The combination of selective serotonin reuptake inhibitors with atypical antipsychotic drugs exhibits beneficial effects in treatment-resistant depression. We investigated the effects of a 2-week treatment with a low fluoxetine dose (3 mg/kg per day) plus a single injection of olanzapine (3 mg/kg) on the dialysate concentration of noradrenaline, dopamine and serotonin (5-HT) in the medial prefrontal cortex of the rat. Chronic fluoxetine increased only 5-HT levels whereas single olanzapine administration increased the concentration of catecholamines and decreased that of 5-HT to a comparable extent in vehicle- and fluoxetine-treated rats. Therefore, it is possible that the therapeutic benefit of this pharmacological combination may not be associated to changes in the cortical concentration of monoamines, but to postsynaptic blockade of monoaminergic receptors.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Mercè Amargós-Bosch, Francesc Artigas, Albert Adell,